

Florida Cancer Innovation Fund

Fiscal Year 2024-25 Funding Opportunity Announcement

ADDENDUM I

February 28, 2025

Changes to the FY 2024-25 Funding Opportunity Announcement:

Page four: Deadlines and Award Timeline Section

The following changes have been made.

Section 1 c: The initial application period has been extended and will remain open until March 28, 2025. Previous closing was January 21, 2025.

Section 1 d: There will be three grant award periods instead of two.

Section 3 c: Now includes an inclusion of a special third application period. Period 3: Applications received by March 28, 2025, will be reviewed by April 25, 2025; Applicants will be notified on or around May 16, 2025.

This special period invites research grant applications that explore innovative non-pharmaceutical interventions for cancer treatment and prevention. Priority will be given to projects that investigate holistic approaches, such as dietary modifications, physical activity programs, mindfulness and stress reduction techniques, and other integrative therapies that may prevent and treat cancer.

Further, this special period will also prioritize for that identifies the repurposing of generic drugs as new treatments for cancer. This presents as a unique opportunity for Florida researchers to propose pathways for widely available generic drugs that may rapidly expand affordable treatment options for cancer patients and identify regulatory barriers and solutions.

Section 3 d and e now read to include the new date of March 28, 2025, and refer to the changes in the periods for review.

- Applications received after March 28, 2025, 11:59 PM ET will not be reviewed.
- Applications received during application period one and two will also be considered
 against other applications received during application period three if not funded in the
 previous application period that they were submitted under.

Section 4: Has been updated to state the total amount of funding available for distribution across the entire cycle and does not break it down by application period.

• Approximately, \$60 million will be available for distribution Florida fiscal year 2024-25.

Page nine: Evaluation Criteria Section

The following changes have been made.

Under bullet 3 additions have been made to highlight areas of preferred research in the area of modifiable risk factors and use of other evidence-based non-pharmaceutical interventions related to cancer prevention and treatment.

3. Additional merit will be awarded to those concentrating on pediatric cancers, research or treatment within rural populations, and studies or interventions targeting modifiable risk

factors such as diet and nutrition or other evidence-based non-pharmaceutical interventions related to cancer prevention and treatment.

4. Additional merit will be awarded to research related to the use of generic drugs for cancer care and treatment.